Literature DB >> 23045701

Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21.

Anindita Roy1, Gillian Cowan, Adam J Mead, Sarah Filippi, Georg Bohn, Aristeidis Chaidos, Oliver Tunstall, Jerry K Y Chan, Mahesh Choolani, Phillip Bennett, Sailesh Kumar, Deborah Atkinson, Josephine Wyatt-Ashmead, Ming Hu, Michael P H Stumpf, Katerina Goudevenou, David O'Connor, Stella T Chou, Mitchell J Weiss, Anastasios Karadimitris, Sten Eirik Jacobsen, Paresh Vyas, Irene Roberts.   

Abstract

The 40-fold increase in childhood megakaryocyte-erythroid and B-cell leukemia in Down syndrome implicates trisomy 21 (T21) in perturbing fetal hematopoiesis. Here, we show that compared with primary disomic controls, primary T21 fetal liver (FL) hematopoietic stem cells (HSC) and megakaryocyte-erythroid progenitors are markedly increased, whereas granulocyte-macrophage progenitors are reduced. Commensurately, HSC and megakaryocyte-erythroid progenitors show higher clonogenicity, with increased megakaryocyte, megakaryocyte-erythroid, and replatable blast colonies. Biased megakaryocyte-erythroid-primed gene expression was detected as early as the HSC compartment. In lymphopoiesis, T21 FL lymphoid-primed multipotential progenitors and early lymphoid progenitor numbers are maintained, but there was a 10-fold reduction in committed PreproB-lymphoid progenitors and the functional B-cell potential of HSC and early lymphoid progenitor is severely impaired, in tandem with reduced early lymphoid gene expression. The same pattern was seen in all T21 FL samples and no samples had GATA1 mutations. Therefore, T21 itself causes multiple distinct defects in FL myelo- and lymphopoiesis.

Entities:  

Mesh:

Year:  2012        PMID: 23045701      PMCID: PMC3491522          DOI: 10.1073/pnas.1211405109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Global up-regulation of chromosome 21 gene expression in the developing Down syndrome brain.

Authors:  Rong Mao; Carol L Zielke; H Ronald Zielke; Jonathan Pevsner
Journal:  Genomics       Date:  2003-05       Impact factor: 5.736

2.  Transcriptome analysis of human autosomal trisomy.

Authors:  David R FitzPatrick; Jacqueline Ramsay; Niolette I McGill; Mary Shade; Andrew D Carothers; Nicholas D Hastie
Journal:  Hum Mol Genet       Date:  2002-12-15       Impact factor: 6.150

Review 3.  Chromosome 21 and down syndrome: from genomics to pathophysiology.

Authors:  Stylianos E Antonarakis; Robert Lyle; Emmanouil T Dermitzakis; Alexandre Reymond; Samuel Deutsch
Journal:  Nat Rev Genet       Date:  2004-10       Impact factor: 53.242

4.  Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML.

Authors:  H Hasle; J Abrahamsson; M Arola; A Karow; A O'Marcaigh; D Reinhardt; D K H Webb; E van Wering; B Zeller; C M Zwaan; P Vyas
Journal:  Leukemia       Date:  2007-12-06       Impact factor: 11.528

5.  Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood.

Authors:  Ravindra Majeti; Christopher Y Park; Irving L Weissman
Journal:  Cell Stem Cell       Date:  2007-12-13       Impact factor: 24.633

6.  Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia.

Authors:  Nicolas Goardon; Emanuele Marchi; Ann Atzberger; Lynn Quek; Anna Schuh; Shamit Soneji; Petter Woll; Adam Mead; Kate A Alford; Raj Rout; Salma Chaudhury; Amanda Gilkes; Steve Knapper; Kheira Beldjord; Suriya Begum; Susan Rose; Nicola Geddes; Mike Griffiths; Graham Standen; Alexander Sternberg; Jamie Cavenagh; Hannah Hunter; David Bowen; Sally Killick; Lisa Robinson; Andrew Price; Elizabeth Macintyre; Paul Virgo; Alan Burnett; Charles Craddock; Tariq Enver; Sten Eirik W Jacobsen; Catherine Porcher; Paresh Vyas
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 31.743

7.  GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.

Authors:  Johann K Hitzler; Joseph Cheung; Yue Li; Stephen W Scherer; Alvin Zipursky
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

8.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.

Authors:  Joshua Wechsler; Marianne Greene; Michael A McDevitt; John Anastasi; Judith E Karp; Michelle M Le Beau; John D Crispino
Journal:  Nat Genet       Date:  2002-08-12       Impact factor: 38.330

9.  Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations.

Authors:  Oliver Tunstall-Pedoe; Anindita Roy; Anastasios Karadimitris; Josu de la Fuente; Nicholas M Fisk; Phillip Bennett; Alice Norton; Paresh Vyas; Irene Roberts
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

10.  Treatment and prognostic impact of transient leukemia in neonates with Down syndrome.

Authors:  Jan-Henning Klusmann; Ursula Creutzig; Martin Zimmermann; Michael Dworzak; Norbert Jorch; Claudia Langebrake; Arnulf Pekrun; Katarina Macakova-Reinhardt; Dirk Reinhardt
Journal:  Blood       Date:  2008-01-08       Impact factor: 22.113

View more
  66 in total

1.  A literature search tool for intelligent extraction of disease-associated genes.

Authors:  Jae-Yoon Jung; Todd F DeLuca; Tristan H Nelson; Dennis P Wall
Journal:  J Am Med Inform Assoc       Date:  2013-09-02       Impact factor: 4.497

2.  Differentiating skin-limited and multisystem Langerhans cell histiocytosis.

Authors:  Stephen J Simko; Benjamin Garmezy; Harshal Abhyankar; Philip J Lupo; Rikhia Chakraborty; Karen Phaik Har Lim; Albert Shih; M John Hicks; Teresa S Wright; Moise L Levy; Kenneth L McClain; Carl E Allen
Journal:  J Pediatr       Date:  2014-10-21       Impact factor: 4.406

3.  Leukaemia: Early changes.

Authors:  Nicola McCarthy
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

4.  Myeloid Proliferations Associated with Down Syndrome.

Authors:  Alan B Cantor
Journal:  J Hematop       Date:  2014-12-14       Impact factor: 0.196

5.  Too much to differentiate: aneuploidy promotes proliferation and teratoma formation in embryonic stem cells.

Authors:  Zuzana Storchová
Journal:  EMBO J       Date:  2016-09-28       Impact factor: 11.598

6.  Pluripotent stem cells reveal erythroid-specific activities of the GATA1 N-terminus.

Authors:  Marta Byrska-Bishop; Daniel VanDorn; Amy E Campbell; Marisol Betensky; Philip R Arca; Yu Yao; Paul Gadue; Fernando F Costa; Richard L Nemiroff; Gerd A Blobel; Deborah L French; Ross C Hardison; Mitchell J Weiss; Stella T Chou
Journal:  J Clin Invest       Date:  2015-01-26       Impact factor: 14.808

7.  GATA1s exerts developmental stage-specific effects in human hematopoiesis.

Authors:  Sofia Gialesaki; Anna Katharina Mahnken; Lena Schmid; Maurice Labuhn; Raj Bhayadia; Dirk Heckl; Jan-Henning Klusmann
Journal:  Haematologica       Date:  2018-03-22       Impact factor: 9.941

8.  Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder.

Authors:  Yehudit Birger; Liat Goldberg; Timothy M Chlon; Benjamin Goldenson; Inna Muler; Ginette Schiby; Jasmin Jacob-Hirsch; Gideon Rechavi; John D Crispino; Shai Izraeli
Journal:  Blood       Date:  2013-05-29       Impact factor: 22.113

9.  Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells.

Authors:  Stella T Chou; Marta Byrska-Bishop; Joanna M Tober; Yu Yao; Daniel Vandorn; Joanna B Opalinska; Jason A Mills; John Kim Choi; Nancy A Speck; Paul Gadue; Ross C Hardison; Richard L Nemiroff; Deborah L French; Mitchell J Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

10.  Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells.

Authors:  Glenn A Maclean; Tobias F Menne; Guoji Guo; Danielle J Sanchez; In-Hyun Park; George Q Daley; Stuart H Orkin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.